Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Male or female patients 40 years of age or older.~* Smoking history of at least 10 pack years.~* Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1\<70% of FVC and on stable respiratory medication.~Exclusion Criteria:~* Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.~* Myocardial infarction in past 6 months.~* Unstable or life threatening arrhythmia in past year.~* Hospitalization for NYHA heart failure class III or IV in past year.~* Active tuberculosis.~* Asthma.~* Pulmonary resection.~* Malignancy treated with radiation or chemotherapy in past 5 years.~* Respiratory infection in 4 weeks prior to screening.~* Known hypersensitivity to anticholinergic drugs or components.~* Known moderate to severe renal impairment.~* Known narrow angle glaucoma.~* Significant symptomatic BPH or bladder neck obstruction.~* Need for oxygen therapy \>12 hr/day.~* Use of oral corticosteroids at unstable doses or \>10 mg/day.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).